Labeled Compounds for Cartilage Imaging via Glycosaminoglycan Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques, particularly MRI, face challenges in obtaining high-resolution images of the boundary between bone and cartilage, and are inadequate for early detection of osteoarthritis, often requiring invasive contrast agents that cause discomfort and have toxicity concerns.
Innovation Solution
Development of novel labeled compounds that temporarily bind to cartilage components like glycosaminoglycans, allowing for improved imaging and diagnosis of cartilage health and disorders through enhanced tissue-specific accumulation and reduced invasiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard MRI techniques are used to obtain high resolution images of bone-cartilage boundary, then image resolution is improved, but imaging complexity and difficulty increase
Solution Approach 1:
The patent introduces cartilage-specific imaging agents (labeled compounds of formulas I-XII) as intermediaries that selectively bind to cartilage components. These agents accumulate in cartilage tissue, providing intrinsic contrast that simplifies the imaging process and enables high-resolution visualization of the bone-cartilage boundary without requiring complex imaging sequences or post-processing
2Measurement precision
If contrast agents are injected to improve MRI contrast, then imaging contrast is improved, but patient discomfort and toxicity increase
Solution Approach 1:
The patent uses small molecule imaging agents that temporarily bind to cartilage components as intermediaries to achieve tissue-specific contrast. These agents provide the necessary contrast enhancement while having minimal toxic effects and causing little patient discomfort compared to traditional contrast agents
Solution Approach 2:
The patent employs labeled compounds with specific molecular structures (formulas I-XII) that have optimized parameters for cartilage binding affinity and temporary residence. The labeling (radioactive or fluorescent) provides detectable signal without significantly altering the binding characteristics, achieving high contrast with minimal harm
3Reliability
If standard MRI is used to detect early osteoarthritis, then detection capability is improved, but sensitivity to early stages decreases
Solution Approach 1:
The patent introduces cartilage-specific imaging agents as intermediaries that selectively accumulate in cartilage tissue. This targeted accumulation provides high sensitivity for detecting early osteoarthritis by visualizing biochemical changes in cartilage before structural damage becomes apparent on standard MRI
Solution Approach 2:
The patent uses labeled compounds with radioactive or fluorescent labels that produce detectable signals. The labeling allows for highly sensitive detection of cartilage integrity and early osteoarthritis by providing a strong signal that can detect subtle changes in cartilage composition and structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-resolution imaging of cartilage health with reduced patient discomfort and increased sensitivity to early stages of osteoarthritis, providing a non-invasive method for monitoring cartilage health and diagnosing cartilage disorders.
Implementation Method 1
novel labeled compounds that temporarily bind to cartilage components like glycosaminoglycans, allowing for improved imaging and diagnosis of cartilage health
Implementation Method 2
MRI is a well-known medical imaging technique in which areas of the body are visualized via the nuclei of selected atoms, especially hydrogen nuclei. The MRI signal depends upon the environment surrounding the visualized nuclei and their longitudinal and transverse relaxation times, T1 and T2
Implementation Method 3
labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
Data Source
AI summary
Novel labeled compounds and metabolites thereof are disclosed, as well as pharmaceutical compositions including the compounds, and methods of using the labeled and unlabeled compounds, and specifically, 2-Amino-5-guanidino-pentanoic acid (3-{4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide and metabolites thereof, for imaging, detecting and assessing disorders and diseases, such as arthritis and, more specifically, osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage. Also, pharmaceutical compositions comprising labeled and/or unlabeled 1,4-Bis(3-aminopropyl)piperazine are disclosed and methods of using the same.